A Placebo-Controlled, Single-Blind, Randomised, Parallel Group, 28-Day Repeat Dose Study to Investigate the Tolerability, Safety and Steady State Pharmacokinetics of GSK372475 [NS-2359] in Healthy Young and Elderly, Male and Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2017
At a glance
- Drugs NS 2359 (Primary)
- Indications Depressive disorders
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 26 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Oct 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 23 Aug 2008 New trial record.